Impact of IL-10 gene promoter -1082 (G/A) polymorphism in B cell chronic lymphocytic leukemia

Abstract

Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia among western population. Many interesting reports suggest the role of IL-10 polymorphisms in CLL oncogenesis. This study aimed to study the relation between IL-10 (rs1800896)-1082 (G/A) gene polymorphism and the risk of development of B cell chronic lymphocytic leukemia and its impact on the patient outcome. IL-10 (rs1800896)-1082 (G/A) gene polymorphism was assessed in fifty patients with chronic lymphocytic leukemia as well as 50 age and sex-matched apparently healthy controls using polymerase chain reaction (PCR). The IL-10 (rs1800896) AG hetero, GG homo, AG + GG genotypes, and G allele showed significantly higher frequency (P > 0.001) in CLL cases when compared to control groups. The genotype AG + GG were significantly associated with advanced stages (P > 0.001), short time to first treatment (TFT) (P = 0.032), shorter progression free survival (PFS) (P = 0.044), and lower response to treatment (P = 0.003) as compared to wild genotype (AA wild). The IL-10 (rs1800896) genotypes (GG, AG) might have a role in the pathogenesis of CLL and have deleterious impact on the CLL patient’s outcome.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. Author (2016) An international prognostic index for patients with chronic lymphocytic leukemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol 17(6):779–790

    Article  Google Scholar 

  2. Berglund M, Thunberg U, Roos G, Rosenquist R, Enblad G (2005) The interleukin-10 gene promoter polymorphism (-1082) does not correlate with clinical outcome in diffuse large B-cell lymphoma. Blood 105(12):4894–4895

    CAS  Article  PubMed Central  Google Scholar 

  3. Blay JY, Burdin N, Rousset F, Lenoir G, Biron P, Philip T, Banchereau J, Favrot MC (1993) Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. Blood 82(7):2169–2174

    CAS  Article  PubMed Central  Google Scholar 

  4. Cervenak L, Morbidelli L, Donati D, Donnini S, Kambayashi T, Wilson J, Axelson H, Castaños-Velez E, Lungren H, Waal Malefyt R, Harris H, Ziche M, Teresa BM (2000) Abolished antigenicity and tumorigenicity of Burkitt lymphoma by interleukin- 10. Blood 96:2568–2573

    CAS  Article  PubMed Central  Google Scholar 

  5. Domingo-Domènech E, Benavente Y, González-Barca E, Montalban C, Gumà J, Bosch R, Rothman N (2007) Impact of interleukin-10 polymorphisms (-1082 and -3575) on the survival of patients with lymphoid neoplasms. Haematologica 92(11):1475–1481

    Article  PubMed Central  Google Scholar 

  6. Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M, Buske C (2015) Chronic lymphocytic leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(suppl_5):78–v84

    Article  Google Scholar 

  7. Groux H, Bigler M, de Vries JE, Roncarolo MG (1998) Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells. J Immunol 60:3188–3193

    Google Scholar 

  8. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, Kipps TJ (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) guidelines. Blood 111(12):5446–5456

    CAS  Article  PubMed Central  Google Scholar 

  9. Hamblin TJ (2009) Just exactly how common is CLL? Leuk Res 33(11):1452–1453

    Article  PubMed Central  Google Scholar 

  10. Hartmann C, Lennartz K, Ibrahim H, Coz A, Kasper Y, Lenz C, & Polidori M (2016) Stable 16-year storage of DNA purified with the QIAamp® DNA Blood Mini Kit. Application note QIAGEN GmbH, QIAGEN Straße 1, Hilden, Germany

  11. Herishanu Y, Katz BZ, Lipsky A, Wiestner A (2013) Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications. Hematol Oncol Clin 27(2):173–206

    Article  Google Scholar 

  12. Lech-Maranda E, Baseggio L, Bienvenu J, Charlot C, Berger F, Rigal D, Salles G (2004) Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood 103(9):3529–3534

    CAS  Article  PubMed Central  Google Scholar 

  13. Lech-Maranda E, Mlynarski W, Grzybowska-Izydorczyk O, Borowiec M, Pastorczak A, Cebula-Obrzut B, Robak T (2013) Polymorphisms of TNF and IL- 10 genes and clinical outcome of patients with chronic lymphocytic leukemia. Genes Chromosom Cancer 52(3):287–296

    CAS  Article  PubMed Central  Google Scholar 

  14. Murray PJ (2007) The JAK-STAT signaling pathway: input and output integration. J Immunol 178(5):2623–2629

    CAS  Article  Google Scholar 

  15. Ouyang W, Rutz S, Crellin NK, Valdez PA, Hymowitz SG (2011) Regulation and functions of the IL-10 family of cytokines in inflammation and disease. Annu Rev Immunol 29:71–109

    CAS  Article  PubMed Central  Google Scholar 

  16. Ovsepyan VA, Gabdulkhakova AK, Shubenkiva AA, Zotina EN (2015) Role of interleukin-10 gene promoter region polymorphism in the development of chronic lymphoid leukemia. Bull Exp Biol Med 160(2):275–277

    CAS  Article  PubMed Central  Google Scholar 

  17. Rahman HAA, Khorshied MM, Khorshid OMR, Mourad HM (2018) Association of Interleukin-2-330T/G and Interleukin-10-1082A/G genetic polymorphisms with B-cell non-Hodgkin lymphoma in a cohort of Egyptians. Turkish J Hematol 35(2):99–108

    Article  Google Scholar 

  18. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS (1975) Clinical staging of chronic lymphocytic leukemia. Blood 46(2):219–234

    CAS  Article  Google Scholar 

  19. Sabat R, Grütz G, Warszawska K, Kirsch S, Witte E, Wolk K, Geginat J (2010) Biology of interleukin-10. Cytokine Growth Factor Rev 21(5):331–344

    CAS  Article  Google Scholar 

  20. Sami RM, Nasr AS, Ibrahim NY, Darweesh DO, El Hussieny NM (2012) Association of IL-10 gene promoter polymorphisms and non-Hodgkin lymphoma in Egyptian patients, relation to susceptibility, correlation with survival. Comp Clin Pathol 21(6):1407–1415

    CAS  Article  Google Scholar 

  21. Schoof N, Franklin J, Fürst R, Zander T, Von Bonin F, Peyrade F, Re D (2013) Interleukin-10 gene polymorphisms are associated with freedom from treatment failure for patients with Hodgkin lymphoma. Oncologist 18(1):80–89

    CAS  Article  PubMed Central  Google Scholar 

  22. Stickel J, Kowalewski D, Rammensee HG, Stevanovic S (2018) Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL). U.S. Patent Application No.; 10/000,533

  23. Trinchieri G (2007) Interleukin-10 production by effector T cells: Th1 cells show self-control. J Exp Med 204(2):239–243

    CAS  Article  PubMed Central  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Salah Aref.

Ethics declarations

This study did not include animals.

Conflict of interest

The authors declare that they have no conflict of interest.

Informed consent

Informed consent was taken from all subjects who participated in this study.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Aref, S., Mohamed, A., El Shehawy, H. et al. Impact of IL-10 gene promoter -1082 (G/A) polymorphism in B cell chronic lymphocytic leukemia. Comp Clin Pathol (2020). https://doi.org/10.1007/s00580-020-03139-3

Download citation

Keywords

  • CLL
  • IL-10
  • SNP